{"gene":"OTC","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":1985,"finding":"The human OTC gene was localized to chromosomal region Xp11.4-Xp21 using somatic cell hybrids, and a frequent RFLP (MspI) was identified; the gene encodes ornithine transcarbamylase, a mitochondrial enzyme of the urea cycle.","method":"Somatic cell hybrid mapping, Northern blot, cDNA cloning","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — direct chromosomal mapping with somatic cell hybrids, corroborated by Northern blot and cDNA isolation","pmids":["3839070"],"is_preprint":false},{"year":1991,"finding":"Newly synthesized mouse OTC precursor (pOTC) is efficiently imported into mitochondria following adenovirus-mediated gene delivery in spf(ash) hepatocytes, with mitochondrial localization confirmed by electron microscope immunolocalization; human OTC precursor showed a block in mitochondrial translocation in the same system.","method":"Electron microscope immunolocalization, quantitative morphometry, subcellular fractionation after adenoviral OTC gene delivery","journal":"Molecular medicine","confidence":"High","confidence_rationale":"Tier 1-2 — ultrastructural immunolocalization with functional comparison of mouse vs. human OTC precursor mitochondrial import","pmids":["10448647"],"is_preprint":false},{"year":1991,"finding":"Rescue of OTC activity in BWTG3 hepatoma cells (which lack OTC) requires fusion with OTC-positive hepatocytes; the silent OTC gene in hepatoma cells cannot be reactivated by hormones or azacytidine alone, indicating cell-context-dependent transcriptional regulation requiring a liver-specific trans-acting factor.","method":"Cell fusion, enzyme activity assay, azacytidine treatment, hormone induction","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 — genetic complementation via cell fusion with functional readout, single lab","pmids":["1860901"],"is_preprint":false},{"year":1993,"finding":"Zinc supplementation increases hepatic OTC enzymatic activity in cirrhotic rats, with OTC activity positively correlated with serum and hepatic zinc content, suggesting zinc as a modulator of OTC catalytic function.","method":"In vivo zinc supplementation, radiochemical OTC enzyme activity assay in cirrhotic rat liver","journal":"Journal of trace elements and electrolytes in health and disease","confidence":"Low","confidence_rationale":"Tier 3 — single in vivo supplementation study, correlational, no direct mechanistic dissection","pmids":["8019156"],"is_preprint":false},{"year":1995,"finding":"Small intestinal OTC activity is more important than hepatic OTC activity for preventing urinary orotic acid excretion; in spf-ash mice carrying an OTC transgene, elevated intestinal OTC activity (30% of control) prevents excess orotic aciduria, whereas hepatic activity alone at ~10% is insufficient.","method":"OTC transgenic rescue in spf-ash mice, measurement of urinary orotic acid vs. tissue OTC activity","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic complementation with quantitative tissue-specific activity measurements","pmids":["7827141"],"is_preprint":false},{"year":1997,"finding":"Mutations P225L and P225R in OTC codon 225 result in undetectable OTC protein antigen in liver despite near-normal residual enzyme properties (normal pH dependence, Km, stability), suggesting the mutations impair efficient import/folding of the precursor into mitochondria rather than catalytic function per se.","method":"Immunoblot for OTC antigen, enzyme kinetic assays (Km for ornithine and carbamoyl phosphate, thermal stability, urea stability), sequencing","journal":"Journal of inherited metabolic disease","confidence":"Medium","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical methods (enzyme kinetics, stability, antigen quantification) in a single study","pmids":["9427144"],"is_preprint":false},{"year":1997,"finding":"Transfection of COS1 cells with the Leu148Phe mutant OTC cDNA yielded undetectable OTC enzyme activity, confirming this missense mutation abolishes OTC catalytic function.","method":"Transient transfection (COS1 cells), enzyme activity assay","journal":"American journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro expression assay with direct functional readout; single study","pmids":["9056557"],"is_preprint":false},{"year":2006,"finding":"In OTC-deficient spf(ash) mice, reduced citrulline availability (30–50% of wild-type) leads to reduced de novo arginine production and a 50% reduction in whole-body nitric oxide production under basal conditions, demonstrating that OTC-derived citrulline is required to sustain NO synthesis via the citrulline-arginine-NO pathway.","method":"Stable isotope tracer infusion (LC-MS measurement of [15N]citrulline→[15N]arginine→NO flux) in vivo in spf(ash) mice","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 — in vivo isotopic flux analysis with multiple tracers measuring citrulline production, de novo arginine synthesis, and NO production simultaneously","pmids":["18697914"],"is_preprint":false},{"year":2006,"finding":"Ornithine supplementation in spf(ash) mice restores ureagenesis, reduces plasma ammonia, and normalizes 15N transfer from glutamine to urea, demonstrating that ornithine availability is rate-limiting for OTC-dependent urea cycle flux under conditions of unbalanced amino acid loads.","method":"Multiple stable isotope tracer infusion in vivo ([13C18O]urea, [15N]glutamine tracers) in conscious spf(ash) mice","journal":"The Journal of nutrition","confidence":"High","confidence_rationale":"Tier 1 — in vivo multi-tracer kinetic analysis with rigorous controls; directly demonstrates ornithine as rate-limiting substrate for OTC","pmids":["16772445"],"is_preprint":false},{"year":2010,"finding":"A heterozygous single nucleotide substitution (c.-366A>G) in the OTC promoter disrupts the interaction of the promoter with an upstream enhancer, reducing transcriptional activity; the OTC promoter requires this upstream enhancer for full activity, and the interaction is necessary for liver-specific OTC expression.","method":"Dual luciferase reporter assay, transcription start site mapping, promoter-enhancer interaction functional studies","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 — functional reporter assay with mutagenesis and promoter-enhancer dissection; single lab","pmids":["20127982"],"is_preprint":false},{"year":2015,"finding":"The spf/ash mutation (c.386G>A; p.R129H) causes aberrant splicing via partial use of a cryptic 5' splice site 48 bp into intron 4 of the mouse Otc gene, resulting in partial intron 4 retention. In the equivalent human OTC patient, the same nucleotide change instead causes exon 4 skipping or use of a cryptic splice site at c.386+4. Both result in ~3–6% residual OTC enzyme activity. The divergent splicing outcomes are reproduced in minigene assays.","method":"RT-PCR of liver tissue, minigene splicing assay, antisense oligonucleotide experiments, enzyme activity assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 — splicing mechanism dissected in native tissue and minigene, with species comparison and functional enzyme activity","pmids":["25853564"],"is_preprint":false},{"year":2017,"finding":"OTC protein is expressed in a small subset of nitrergic (nNOS-positive) neurons in the adult human brain, as shown by double immunolabeling for OTC and nNOS, suggesting that OTC-generated citrulline supports NO production in these neurons by enhancing arginine bioavailability.","method":"Double immunofluorescence labeling (OTC + nNOS) in human brain sections","journal":"Metabolic brain disease","confidence":"Low","confidence_rationale":"Tier 3 — single immunohistochemical study, functional implication inferred, not directly tested","pmids":["28868581"],"is_preprint":false},{"year":2021,"finding":"Subtle intronic sequence differences at positions +10-11 downstream of the OTC exon 4 cryptic 5'ss confer preferential binding to the TIA1 splicing factor in the mouse but not human genomic context, explaining species-specific splicing outcomes from the c.386G>A mutation and differential responsiveness to engineered U1snRNA therapeutics.","method":"RNA pulldown assay (TIA1 binding), minigene splicing assay with nucleotide swap mutants, U1snRNA co-expression in hepatoma cells","journal":"Molecular medicine","confidence":"High","confidence_rationale":"Tier 1-2 — mechanistic dissection with RNA pulldown, mutagenesis, and functional splicing readout; multiple orthogonal methods","pmids":["34906067"],"is_preprint":false},{"year":2021,"finding":"Common polymorphic OTC variants (p.Lys46Arg and p.Gln270Arg) modulate OTC enzymatic activity in cis: the minor allele of p.Gln270Arg significantly enhanced wild-type OTC activity and partially rescued activity of the pathogenic p.Arg40His allele in vitro.","method":"In vitro enzymatic activity assay of recombinant OTC variants, structural analysis","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 1 — direct in vitro enzymatic assay with multiple allelic combinations; single lab","pmids":["34015158"],"is_preprint":false},{"year":2022,"finding":"An OTC promoter variant (c.-106C>A) in a conserved HNF4α binding site reduces OTC promoter-driven expression >5-fold in a dual-luciferase assay, and this reduction is maintained in the presence of the upstream OTC enhancer, mechanistically explaining late-onset, stress-triggered hyperammonemia in hemizygous males.","method":"Dual-luciferase reporter assay with wild-type and mutant OTC promoter constructs, with and without upstream enhancer","journal":"Journal of inherited metabolic disease","confidence":"Medium","confidence_rationale":"Tier 2 — functional promoter assay with enhancer dissection; single lab but clear quantitative result","pmids":["35605046"],"is_preprint":false},{"year":2023,"finding":"A high-throughput functional assay measuring OTC activity in yeast for 1,570 individual amino acid substitutions (84% of all SNV-accessible missense mutations) identified a 13 amino acid domain (the SMG loop) whose function is required in human cells but not in yeast, and demonstrated score ranges corresponding to clinically relevant levels of OTC activity impairment.","method":"High-throughput yeast-based functional assay for OTC activity, clinical variant benchmarking, protein structure analysis","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1 — large-scale functional assay covering most missense variants, validated against known clinical classifications, with structural interpretation","pmids":["37146589"],"is_preprint":false}],"current_model":"OTC (ornithine transcarbamylase) is a mitochondrial enzyme that catalyzes the conversion of ornithine and carbamoyl phosphate to citrulline as the second step of the urea cycle; its precursor is synthesized in the cytoplasm and imported into mitochondria, where it functions as a trimer, and OTC-derived citrulline is required for de novo arginine synthesis and basal nitric oxide production, while its transcription is controlled by a liver-specific promoter-enhancer interaction dependent on HNF4α binding, and its pre-mRNA splicing is regulated by context-specific splice-site recognition factors including TIA1."},"narrative":{"teleology":[{"year":1985,"claim":"Mapping OTC to Xp11.4–Xp21 and cloning its cDNA established the gene's chromosomal identity and linked it to X-linked ornithine transcarbamylase deficiency.","evidence":"Somatic cell hybrid mapping, Northern blot, and cDNA cloning in human cells","pmids":["3839070"],"confidence":"High","gaps":["Gene structure (intron–exon organization) not yet defined","No functional reconstitution of enzyme activity from cloned cDNA"]},{"year":1991,"claim":"Demonstration that the OTC precursor must be imported into mitochondria for function—and that liver-specific trans-acting factors are required for OTC transcription—established two distinct regulatory layers: post-translational targeting and tissue-restricted gene expression.","evidence":"Electron microscope immunolocalization after adenoviral gene delivery (mitochondrial import); cell fusion experiments showing OTC reactivation only upon complementation with OTC-positive hepatocytes","pmids":["10448647","1860901"],"confidence":"High","gaps":["Identity of the liver-specific trans-acting factor(s) not determined","Species-specific differences in precursor import (mouse vs. human) unexplained"]},{"year":1995,"claim":"Transgenic rescue in spf-ash mice revealed that intestinal OTC activity contributes more than hepatic activity to preventing orotic aciduria, establishing tissue-specific functional contributions of OTC beyond the liver.","evidence":"OTC transgene expression in spf-ash mice with quantitation of urinary orotic acid and tissue OTC activity","pmids":["7827141"],"confidence":"Medium","gaps":["Mechanism of intestinal vs. hepatic OTC contribution to whole-body nitrogen balance not fully dissected","Single transgenic line studied"]},{"year":1997,"claim":"Characterization of disease-causing missense mutations (P225L/R, L148F) separated catalytic defects from import/folding defects, revealing that many pathogenic OTC mutations act by destabilizing the precursor rather than abolishing enzymatic activity.","evidence":"Enzyme kinetics (Km, thermal stability) and immunoblot of mutant OTC in patient liver and COS1 transfection","pmids":["9427144","9056557"],"confidence":"Medium","gaps":["No in vitro import assay to directly measure translocation efficiency of mutant precursors","Structural basis of folding defects unknown at atomic resolution"]},{"year":2006,"claim":"Isotopic flux analyses in spf-ash mice demonstrated that OTC-derived citrulline is rate-limiting for de novo arginine synthesis and whole-body NO production, and that ornithine supply is rate-limiting for OTC-dependent ureagenesis, connecting OTC to systemic nitrogen and NO metabolism.","evidence":"In vivo stable isotope tracer infusion (15N-citrulline→arginine→NO; 13C-urea) in conscious spf-ash mice","pmids":["18697914","16772445"],"confidence":"High","gaps":["Whether citrulline supplementation can fully restore NO production independent of OTC not tested","Contribution of extrahepatic OTC to citrulline-arginine-NO pathway not quantified"]},{"year":2010,"claim":"Identification of a promoter–enhancer interaction required for full OTC transcription, disrupted by the c.−366A>G variant, defined the cis-regulatory architecture governing liver-specific OTC expression.","evidence":"Dual-luciferase reporter assay with promoter-enhancer constructs and mutagenesis","pmids":["20127982"],"confidence":"Medium","gaps":["Chromatin-level interaction (e.g. 3C/Hi-C) not confirmed","Trans-acting factors mediating the enhancer–promoter loop not identified at this stage"]},{"year":2015,"claim":"Dissection of the spf-ash mutation (c.386G>A) revealed that the same nucleotide change causes distinct aberrant splicing events in mouse (partial intron retention) vs. human (exon skipping), explaining species-specific residual OTC activity and complicating preclinical modeling.","evidence":"RT-PCR of liver RNA, minigene splicing assays, and enzyme activity measurement across species","pmids":["25853564"],"confidence":"High","gaps":["Trans-acting factor(s) responsible for species-specific splice-site selection not yet identified"]},{"year":2021,"claim":"The species-specific splicing of the spf-ash allele was traced to differential TIA1 binding at intronic positions +10–11 downstream of the cryptic 5′ splice site, and common polymorphic variants (p.Lys46Arg, p.Gln270Arg) were shown to modulate OTC enzymatic activity in cis, refining the genotype–phenotype landscape.","evidence":"RNA pulldown for TIA1, minigene nucleotide-swap mutagenesis, recombinant OTC enzyme activity assays","pmids":["34906067","34015158"],"confidence":"High","gaps":["Whether TIA1 modulation is therapeutically targetable in patients not established","Structural basis for polymorphic modulation of activity not resolved"]},{"year":2022,"claim":"A promoter variant (c.−106C>A) in a conserved HNF4α binding site was shown to reduce OTC expression >5-fold, mechanistically explaining late-onset hyperammonemia and confirming HNF4α as a key transcriptional regulator of OTC.","evidence":"Dual-luciferase reporter assay with wild-type and mutant promoter ± upstream enhancer","pmids":["35605046"],"confidence":"Medium","gaps":["Direct HNF4α ChIP at the OTC promoter not shown","In vivo validation of this promoter variant's effect on OTC mRNA levels not performed"]},{"year":2023,"claim":"A high-throughput functional assay covering 84% of SNV-accessible missense substitutions created a near-complete variant effect map, identifying a 13-amino-acid SMG loop required in human but not yeast cells and enabling clinical variant classification at scale.","evidence":"Yeast-based OTC activity assay for 1,570 individual substitutions, benchmarked against clinical data and protein structure","pmids":["37146589"],"confidence":"High","gaps":["SMG loop function in human cells not mechanistically dissected","Yeast assay may not capture all mammalian-specific folding/import defects"]},{"year":null,"claim":"Key unresolved questions include the structural basis for how disease mutations differentially affect mitochondrial import versus catalytic function, the full complement of trans-acting factors controlling OTC promoter–enhancer looping in vivo, and whether extrahepatic OTC (intestinal, neuronal) can be therapeutically augmented to compensate for hepatic deficiency.","evidence":"","pmids":[],"confidence":"Low","gaps":["No atomic-resolution structure of human OTC with bound precursor signal peptide","In vivo chromatin conformation at the OTC locus not mapped","Functional significance of neuronal OTC expression not experimentally validated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,7,8,13,15]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,1,5]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[7,8,15]}],"complexes":[],"partners":["TIA1","HNF4A"],"other_free_text":[]},"mechanistic_narrative":"OTC (ornithine transcarbamylase) is a mitochondrial matrix enzyme that catalyzes the condensation of ornithine and carbamoyl phosphate to form citrulline, constituting the second committed step of the urea cycle. OTC-derived citrulline is essential not only for ureagenesis—where ornithine availability is rate-limiting for cycle flux—but also for de novo arginine synthesis and basal nitric oxide production via the citrulline–arginine–NO pathway [PMID:18697914, PMID:16772445]. The OTC precursor is synthesized in the cytoplasm and imported into the mitochondrial matrix, where disease-causing mutations such as P225L/R can impair translocation or folding rather than catalysis per se [PMID:9427144, PMID:10448647]. Liver-specific OTC transcription depends on a promoter–enhancer interaction requiring an HNF4α binding site, and the pre-mRNA is subject to species-specific alternative splicing controlled by differential TIA1 recognition of intronic sequences flanking the spf/ash mutation site [PMID:20127982, PMID:35605046, PMID:34906067]."},"prefetch_data":{"uniprot":{"accession":"P00480","full_name":"Ornithine transcarbamylase, mitochondrial","aliases":["Ornithine carbamoyltransferase, mitochondrial"],"length_aa":354,"mass_kda":39.9,"function":"Catalyzes the second step of the urea cycle, the condensation of carbamoyl phosphate with L-ornithine to form L-citrulline (PubMed:2556444, PubMed:6372096, PubMed:8112735). The urea cycle ensures the detoxification of ammonia by converting it to urea for excretion (PubMed:2556444)","subcellular_location":"Mitochondrion matrix","url":"https://www.uniprot.org/uniprotkb/P00480/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/OTC","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/OTC","total_profiled":1310},"omim":[{"mim_id":"616049","title":"TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 34; TOMM34","url":"https://www.omim.org/entry/616049"},{"mim_id":"608313","title":"ARGINASE 1; ARG1","url":"https://www.omim.org/entry/608313"},{"mim_id":"608307","title":"CARBAMOYL PHOSPHATE SYNTHETASE I; CPS1","url":"https://www.omim.org/entry/608307"},{"mim_id":"313440","title":"SYNAPSIN I; SYN1","url":"https://www.omim.org/entry/313440"},{"mim_id":"312750","title":"RETT SYNDROME; RTT","url":"https://www.omim.org/entry/312750"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":105.7},{"tissue":"liver","ntpm":353.1}],"url":"https://www.proteinatlas.org/search/OTC"},"hgnc":{"alias_symbol":["OTCase","OTCD","OTC1"],"prev_symbol":[]},"alphafold":{"accession":"P00480","domains":[{"cath_id":"3.40.50.1370","chopping":"46-169_331-342","consensus_level":"medium","plddt":97.8219,"start":46,"end":342},{"cath_id":"3.40.50.1370","chopping":"172-266_283-329","consensus_level":"medium","plddt":98.4052,"start":172,"end":329}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P00480","model_url":"https://alphafold.ebi.ac.uk/files/AF-P00480-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P00480-F1-predicted_aligned_error_v6.png","plddt_mean":92.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=OTC","jax_strain_url":"https://www.jax.org/strain/search?query=OTC"},"sequence":{"accession":"P00480","fasta_url":"https://rest.uniprot.org/uniprotkb/P00480.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P00480/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P00480"}},"corpus_meta":[{"pmid":"16786505","id":"PMC_16786505","title":"Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16786505","citation_count":138,"is_preprint":false},{"pmid":"19384294","id":"PMC_19384294","title":"AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice.","date":"2009","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19384294","citation_count":99,"is_preprint":false},{"pmid":"33265032","id":"PMC_33265032","title":"Degradation of tetracycline antibiotics by Arthrobacter nicotianae OTC-16.","date":"2020","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/33265032","citation_count":80,"is_preprint":false},{"pmid":"8860834","id":"PMC_8860834","title":"Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter.","date":"1996","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/8860834","citation_count":53,"is_preprint":false},{"pmid":"23232224","id":"PMC_23232224","title":"Changes in the nitrogen removal performance and the properties of granular sludge in an Anammox system under oxytetracycline (OTC) stress.","date":"2012","source":"Bioresource technology","url":"https://pubmed.ncbi.nlm.nih.gov/23232224","citation_count":52,"is_preprint":false},{"pmid":"3839070","id":"PMC_3839070","title":"Gene for OTC: characterisation and linkage to Duchenne muscular dystrophy.","date":"1985","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/3839070","citation_count":51,"is_preprint":false},{"pmid":"3422211","id":"PMC_3422211","title":"Analysis of linkage relationships of X-linked retinitis pigmentosa with the following Xp loci: L1.28, OTC, 754, XJ-1.1, pERT87, and C7.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3422211","citation_count":50,"is_preprint":false},{"pmid":"10561504","id":"PMC_10561504","title":"OTC and AUL1, two convergent and overlapping genes in the nuclear genome of Arabidopsis thaliana.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10561504","citation_count":48,"is_preprint":false},{"pmid":"19138872","id":"PMC_19138872","title":"High-frequency detection of deletions and variable rearrangements at the ornithine transcarbamylase (OTC) locus by oligonucleotide array CGH.","date":"2009","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19138872","citation_count":45,"is_preprint":false},{"pmid":"8365726","id":"PMC_8365726","title":"Four novel gene mutations in five Japanese male patients with neonatal or late onset OTC deficiency: application of PCR-single-strand conformation polymorphisms for all exons and adjacent introns [corrected].","date":"1993","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8365726","citation_count":44,"is_preprint":false},{"pmid":"27070778","id":"PMC_27070778","title":"Frequency and Pathophysiology of Acute Liver Failure in Ornithine Transcarbamylase Deficiency (OTCD).","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27070778","citation_count":42,"is_preprint":false},{"pmid":"31049841","id":"PMC_31049841","title":"Therapeutic Role of a Cysteine Precursor, OTC, in Ischemic Stroke Is Mediated by Improved Proteostasis in Mice.","date":"2019","source":"Translational stroke research","url":"https://pubmed.ncbi.nlm.nih.gov/31049841","citation_count":42,"is_preprint":false},{"pmid":"28283349","id":"PMC_28283349","title":"AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.","date":"2017","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28283349","citation_count":41,"is_preprint":false},{"pmid":"22133298","id":"PMC_22133298","title":"Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome.","date":"2011","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22133298","citation_count":40,"is_preprint":false},{"pmid":"8163168","id":"PMC_8163168","title":"Sequences of the oxytetracycline polyketide synthase-encoding otc genes from Streptomyces rimosus.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8163168","citation_count":40,"is_preprint":false},{"pmid":"20031247","id":"PMC_20031247","title":"Adult-onset ornithine transcarbamylase (OTC) deficiency unmasked by the Atkins' diet.","date":"2009","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/20031247","citation_count":39,"is_preprint":false},{"pmid":"25994866","id":"PMC_25994866","title":"Clinical outcomes and the mutation spectrum of the OTC gene in patients with ornithine transcarbamylase deficiency.","date":"2015","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25994866","citation_count":38,"is_preprint":false},{"pmid":"17334707","id":"PMC_17334707","title":"Estimation of the total number of disease-causing mutations in ornithine transcarbamylase (OTC) deficiency. Value of the OTC structure in predicting a mutation pathogenic potential.","date":"2007","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/17334707","citation_count":37,"is_preprint":false},{"pmid":"25026867","id":"PMC_25026867","title":"Sudden unexpected fatal encephalopathy in adults with OTC gene mutations-Clues for early diagnosis and timely treatment.","date":"2014","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25026867","citation_count":35,"is_preprint":false},{"pmid":"21850052","id":"PMC_21850052","title":"Sustained correction of OTC deficiency in spf( ash) mice using optimized self-complementary AAV2/8 vectors.","date":"2011","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21850052","citation_count":35,"is_preprint":false},{"pmid":"30660977","id":"PMC_30660977","title":"Action of oxytetracycline (OTC) degrading bacterium and its application in Moving Bed Biofilm Reactor (MBBR) for aquaculture wastewater pre-treatment.","date":"2019","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/30660977","citation_count":35,"is_preprint":false},{"pmid":"18204299","id":"PMC_18204299","title":"Mutation analysis of the ornithine transcarbamylase (OTC) gene in five Japanese OTC deficiency patients revealed two known and three novel mutations including a deep intronic mutation.","date":"2007","source":"The Kobe journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18204299","citation_count":35,"is_preprint":false},{"pmid":"1976142","id":"PMC_1976142","title":"The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockers.","date":"1990","source":"Medical care","url":"https://pubmed.ncbi.nlm.nih.gov/1976142","citation_count":34,"is_preprint":false},{"pmid":"18440262","id":"PMC_18440262","title":"Analysis of mRNA transcripts improves the success rate of molecular genetic testing in OTC deficiency.","date":"2008","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18440262","citation_count":32,"is_preprint":false},{"pmid":"15765438","id":"PMC_15765438","title":"PPI use in the OTC era: who to treat, with what, and for how long?","date":"2005","source":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","url":"https://pubmed.ncbi.nlm.nih.gov/15765438","citation_count":29,"is_preprint":false},{"pmid":"23892094","id":"PMC_23892094","title":"Treatment with the cysteine precursor l-2-oxothiazolidine-4-carboxylate (OTC) implicates taurine deficiency in severity of dystropathology in mdx mice.","date":"2013","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23892094","citation_count":28,"is_preprint":false},{"pmid":"10213023","id":"PMC_10213023","title":"The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists.","date":"1999","source":"Medical care","url":"https://pubmed.ncbi.nlm.nih.gov/10213023","citation_count":27,"is_preprint":false},{"pmid":"9286441","id":"PMC_9286441","title":"The ornithine transcarbamylase (OTC) gene: mutations in 50 Japanese families with OTC deficiency.","date":"1997","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9286441","citation_count":26,"is_preprint":false},{"pmid":"33181436","id":"PMC_33181436","title":"The otc gene of Streptococcus suis plays an important role in biofilm formation, adhesion, and virulence in a murine model.","date":"2020","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33181436","citation_count":26,"is_preprint":false},{"pmid":"32039406","id":"PMC_32039406","title":"Efficient in vivo editing of OTC-deficient patient-derived primary human hepatocytes.","date":"2019","source":"JHEP reports : innovation in hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/32039406","citation_count":25,"is_preprint":false},{"pmid":"25853564","id":"PMC_25853564","title":"Functional characterization of the spf/ash splicing variation in OTC deficiency of mice and man.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25853564","citation_count":22,"is_preprint":false},{"pmid":"9007316","id":"PMC_9007316","title":"Asymptomatic and late-onset ornithine transcarbamylase (OTC) deficiency in males of a five-generation family, caused by an A208T mutation.","date":"1996","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9007316","citation_count":22,"is_preprint":false},{"pmid":"25620158","id":"PMC_25620158","title":"Oculo-facio-cardio-dental (OFCD) syndrome: the first Italian case of BCOR and co-occurring OTC gene deletion.","date":"2015","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/25620158","citation_count":21,"is_preprint":false},{"pmid":"23283608","id":"PMC_23283608","title":"Multidisciplinary management of ornithine transcarbamylase (OTC) deficiency in pregnancy: essential to prevent hyperammonemic complications.","date":"2013","source":"BMJ case reports","url":"https://pubmed.ncbi.nlm.nih.gov/23283608","citation_count":21,"is_preprint":false},{"pmid":"28270654","id":"PMC_28270654","title":"A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation.","date":"2017","source":"The American journal of case reports","url":"https://pubmed.ncbi.nlm.nih.gov/28270654","citation_count":20,"is_preprint":false},{"pmid":"36641845","id":"PMC_36641845","title":"Simultaneous adsorption of Cd(II) and degradation of OTC by activated biochar with ferrate: Efficiency and mechanism.","date":"2023","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/36641845","citation_count":19,"is_preprint":false},{"pmid":"37146589","id":"PMC_37146589","title":"The functional impact of 1,570 individual amino acid substitutions in human OTC.","date":"2023","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37146589","citation_count":18,"is_preprint":false},{"pmid":"19475717","id":"PMC_19475717","title":"Molecular mechanisms underlying large genomic deletions in ornithine transcarbamylase (OTC) gene.","date":"2009","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19475717","citation_count":18,"is_preprint":false},{"pmid":"24108150","id":"PMC_24108150","title":"AAV-encoded OTC activity persisting to adulthood following delivery to newborn spf(ash) mice is insufficient to prevent shRNA-induced hyperammonaemia.","date":"2013","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24108150","citation_count":18,"is_preprint":false},{"pmid":"9056557","id":"PMC_9056557","title":"Familial lethal inheritance of a mutated paternal gene in females causing X-linked ornithine transcarbamylase (OTC) deficiency.","date":"1997","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9056557","citation_count":18,"is_preprint":false},{"pmid":"22595304","id":"PMC_22595304","title":"Plant growth stimulation in Prunus species plantlets by BTH or OTC treatments under in vitro conditions.","date":"2012","source":"Journal of plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22595304","citation_count":17,"is_preprint":false},{"pmid":"34014569","id":"PMC_34014569","title":"OTC deficiency in females: Phenotype-genotype correlation based on a 130-family cohort.","date":"2021","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/34014569","citation_count":17,"is_preprint":false},{"pmid":"8019156","id":"PMC_8019156","title":"Effects of zinc on hepatic ornithine transcarbamylase (OTC) activity.","date":"1993","source":"Journal of trace elements and electrolytes in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/8019156","citation_count":17,"is_preprint":false},{"pmid":"11793483","id":"PMC_11793483","title":"Identification of seven novel missense mutations, two splice-site mutations, two microdeletions and a polymorphic amino acid substitution in the gene for ornithine transcarbamylase (OTC) in patients with OTC deficiency.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/11793483","citation_count":16,"is_preprint":false},{"pmid":"10737985","id":"PMC_10737985","title":"Lymphocyte mRNA analysis of the ornithine transcarbamylase gene in Italian OTCD male patients and manifesting carriers: identification of novel mutations.","date":"2000","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10737985","citation_count":15,"is_preprint":false},{"pmid":"29623395","id":"PMC_29623395","title":"Variable X-chromosome inactivation and enlargement of pericentral glutamine synthetase zones in the liver of heterozygous females with OTC deficiency.","date":"2018","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29623395","citation_count":15,"is_preprint":false},{"pmid":"18697914","id":"PMC_18697914","title":"Reduced citrulline availability by OTC deficiency in mice is related to reduced nitric oxide production.","date":"2008","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18697914","citation_count":15,"is_preprint":false},{"pmid":"18414167","id":"PMC_18414167","title":"Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarbamoylase (OTC) deficiency.","date":"2008","source":"Southern medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/18414167","citation_count":15,"is_preprint":false},{"pmid":"12083811","id":"PMC_12083811","title":"Genetic analysis in nine unrelated Italian patients affected by OTC deficiency: detection of novel mutations in the OTC gene.","date":"2002","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12083811","citation_count":14,"is_preprint":false},{"pmid":"34341372","id":"PMC_34341372","title":"Genomic insights into the antibiotic resistance pattern of the tetracycline-degrading bacterium, Arthrobacter nicotianae OTC-16.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34341372","citation_count":14,"is_preprint":false},{"pmid":"977722","id":"PMC_977722","title":"Propionic acidemia and hyperlysinemia in a case with ornithine transcarbamylase (OTC) deficiency.","date":"1976","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/977722","citation_count":14,"is_preprint":false},{"pmid":"17041896","id":"PMC_17041896","title":"Identification of novel mutations in the human ornithine transcarbamylase (OTC) gene of Korean patients with OTC deficiency and transient expression of the mutant proteins in vitro.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/17041896","citation_count":14,"is_preprint":false},{"pmid":"9521626","id":"PMC_9521626","title":"Selective elevation of glutathione levels in target tissues with L-2-oxothiazolidine-4-carboxylate (OTC) protects against hyperoxia-induced lung damage in protein-energy malnourished rats: implications for a new treatment strategy.","date":"1998","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/9521626","citation_count":13,"is_preprint":false},{"pmid":"2001730","id":"PMC_2001730","title":"Correction of ornithine transcarbamylase (OTC) deficiency in spf-ash mice by introduction of rat OTC gene.","date":"1991","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/2001730","citation_count":12,"is_preprint":false},{"pmid":"2878615","id":"PMC_2878615","title":"Clinical application of DNA analysis in a family with OTC deficiency.","date":"1986","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2878615","citation_count":12,"is_preprint":false},{"pmid":"26826959","id":"PMC_26826959","title":"Performance and microbial community variations in thermophilic anaerobic digesters treating OTC medicated cow manure under different operational conditions.","date":"2016","source":"Bioresource technology","url":"https://pubmed.ncbi.nlm.nih.gov/26826959","citation_count":11,"is_preprint":false},{"pmid":"16772445","id":"PMC_16772445","title":"Ornithine restores ureagenesis capacity and mitigates hyperammonemia in Otc(spf-ash) mice.","date":"2006","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/16772445","citation_count":11,"is_preprint":false},{"pmid":"20127982","id":"PMC_20127982","title":"Disruption of OTC promoter-enhancer interaction in a patient with symptoms of ornithine carbamoyltransferase deficiency.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20127982","citation_count":11,"is_preprint":false},{"pmid":"33228018","id":"PMC_33228018","title":"An Exon-Specific Small Nuclear U1 RNA (ExSpeU1) Improves Hepatic OTC Expression in a Splicing-Defective spf/ash Mouse Model of Ornithine Transcarbamylase Deficiency.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33228018","citation_count":10,"is_preprint":false},{"pmid":"28107167","id":"PMC_28107167","title":"Activity of the liver enzyme ornithine carbamoyltransferase (OTC) in blood: LC-MS/MS assay for non-invasive diagnosis of ornithine carbamoyltransferase deficiency.","date":"2017","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28107167","citation_count":10,"is_preprint":false},{"pmid":"8830175","id":"PMC_8830175","title":"Identification of new mutations in the ornithine transcarbamylase (OTC) gene in Korean families.","date":"1996","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/8830175","citation_count":10,"is_preprint":false},{"pmid":"10502831","id":"PMC_10502831","title":"Identification of a cytogenetic deletion and of four novel mutations (Q69X, I172F, G188V, G197R) affecting the gene for ornithine transcarbamylase (OTC) in Spanish patients with OTC deficiency.","date":"1999","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10502831","citation_count":10,"is_preprint":false},{"pmid":"33263566","id":"PMC_33263566","title":"Alert to US physicians: DHEA, widely used as an OTC androgen supplement, may exacerbate COVID-19.","date":"2021","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33263566","citation_count":9,"is_preprint":false},{"pmid":"16549467","id":"PMC_16549467","title":"Reduced ornithine transcarbamylase activity does not impair ureagenesis in Otc(spf-ash) mice.","date":"2006","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/16549467","citation_count":9,"is_preprint":false},{"pmid":"33489762","id":"PMC_33489762","title":"A deep intronic variant is a common cause of OTC deficiency in individuals with previously negative genetic testing.","date":"2021","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/33489762","citation_count":9,"is_preprint":false},{"pmid":"10597536","id":"PMC_10597536","title":"Influence of experimentally induced theileriosis (Theileria annulata) on the pharmacokinetics of a long-acting formulation of oxytetracycline (OTC-LA) in calves.","date":"1999","source":"Journal of veterinary pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/10597536","citation_count":9,"is_preprint":false},{"pmid":"10448647","id":"PMC_10448647","title":"Efficient mitochondrial import of newly synthesized ornithine transcarbamylase (OTC) and correction of secondary metabolic alterations in spf(ash) mice following gene therapy of OTC deficiency.","date":"1999","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/10448647","citation_count":9,"is_preprint":false},{"pmid":"38634223","id":"PMC_38634223","title":"Are asymptomatic carriers of OTC deficiency always asymptomatic? A multicentric retrospective study of risk using the UCDC longitudinal study database.","date":"2024","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38634223","citation_count":8,"is_preprint":false},{"pmid":"25011434","id":"PMC_25011434","title":"OTC gene in ornithine transcarbamylase deficiency: clinical course and mutational spectrum in seven Korean patients.","date":"2014","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25011434","citation_count":8,"is_preprint":false},{"pmid":"32793520","id":"PMC_32793520","title":"Late-Onset Ornithine Transcarbamylase Deficiency and Variable Phenotypes in Vietnamese Females With OTC Mutations.","date":"2020","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/32793520","citation_count":8,"is_preprint":false},{"pmid":"2575934","id":"PMC_2575934","title":"Structure of the ornithine transcarbamylase (OTC) gene and DNA diagnosis of OTC deficiency.","date":"1989","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2575934","citation_count":8,"is_preprint":false},{"pmid":"35605046","id":"PMC_35605046","title":"A promoter variant in the OTC gene associated with late and variable age of onset hyperammonemia.","date":"2022","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/35605046","citation_count":7,"is_preprint":false},{"pmid":"34015158","id":"PMC_34015158","title":"Common polymorphic OTC variants can act as genetic modifiers of enzymatic activity.","date":"2021","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/34015158","citation_count":7,"is_preprint":false},{"pmid":"3066205","id":"PMC_3066205","title":"The pharmacological profile of non-opioid (OTC) analgesics: aspirin, paracetamol (acetaminophen), ibuprofen, and phenazones.","date":"1988","source":"Agents and actions. Supplements","url":"https://pubmed.ncbi.nlm.nih.gov/3066205","citation_count":7,"is_preprint":false},{"pmid":"8862622","id":"PMC_8862622","title":"Prenatal monitoring in a family at high risk for ornithine transcarbamylase (OTC) deficiency: a new mutation of an A-to-C transversion in position +4 of intron 1 of the OTC gene that is likely to abolish enzyme activity.","date":"1996","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8862622","citation_count":7,"is_preprint":false},{"pmid":"9427144","id":"PMC_9427144","title":"Missense mutations in codon 225 of ornithine transcarbamylase (OTC) result in decreased amounts of OTC protein: a hypothesis on the molecular mechanism of the OTC deficiency.","date":"1997","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/9427144","citation_count":7,"is_preprint":false},{"pmid":"7827141","id":"PMC_7827141","title":"Importance of ornithine transcarbamylase (OTC) deficiency in small intestine for urinary orotic acid excretion: analysis of OTC-deficient spf-ash mice with OTC transgene.","date":"1995","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/7827141","citation_count":6,"is_preprint":false},{"pmid":"2049185","id":"PMC_2049185","title":"X-chromosome inactivation in the liver of female heterozygous OTC-deficient sparse-furash mice.","date":"1991","source":"Biochemical medicine and metabolic biology","url":"https://pubmed.ncbi.nlm.nih.gov/2049185","citation_count":6,"is_preprint":false},{"pmid":"37049037","id":"PMC_37049037","title":"Plasma-Polymerised Antibacterial Coating of Ovine Tendon Collagen Type I (OTC) Crosslinked with Genipin (GNP) and Dehydrothermal-Crosslinked (DHT) as a Cutaneous Substitute for Wound Healing.","date":"2023","source":"Materials (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37049037","citation_count":6,"is_preprint":false},{"pmid":"28868581","id":"PMC_28868581","title":"In human brain ornithine transcarbamylase (OTC) immunoreactivity is strongly expressed in a small number of nitrergic neurons.","date":"2017","source":"Metabolic brain disease","url":"https://pubmed.ncbi.nlm.nih.gov/28868581","citation_count":6,"is_preprint":false},{"pmid":"17179910","id":"PMC_17179910","title":"The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial.","date":"2006","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/17179910","citation_count":6,"is_preprint":false},{"pmid":"38052940","id":"PMC_38052940","title":"Monitoring of over-the-counter (OTC) and COVID-19 treatment drugs complement wastewater surveillance of SARS-CoV-2.","date":"2023","source":"Journal of exposure science & environmental epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/38052940","citation_count":5,"is_preprint":false},{"pmid":"17044854","id":"PMC_17044854","title":"Mutational spectrum and linkage disequilibrium patterns at the ornithine transcarbamylase gene (OTC).","date":"2006","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17044854","citation_count":5,"is_preprint":false},{"pmid":"33550136","id":"PMC_33550136","title":"Generation of a human induced pluripotent stem cell line (SDQLCHi036-A) from a patient with ornithine transcarbamylase deficiency carrying a deletion involving 3-9 exons of OTC gene.","date":"2021","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33550136","citation_count":5,"is_preprint":false},{"pmid":"7208155","id":"PMC_7208155","title":"Ornithine transcarbamylase (OTC) in white blood cells.","date":"1980","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/7208155","citation_count":5,"is_preprint":false},{"pmid":"34906067","id":"PMC_34906067","title":"OTC intron 4 variations mediate pathogenic splicing patterns caused by the c.386G>A mutation in humans and spfash mice, and govern susceptibility to RNA-based therapies.","date":"2021","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/34906067","citation_count":5,"is_preprint":false},{"pmid":"12402347","id":"PMC_12402347","title":"H intragenic polymorphisms and haplotype analysis in the ornithine transcarbamylase (OTC) gene and their relevance for tracking the inheritance of OTC deficiency.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12402347","citation_count":5,"is_preprint":false},{"pmid":"19055470","id":"PMC_19055470","title":"Mutation screening of the medium-chain acyl-CoA dehydrogenase (MCAD) and the ornithine transcarbamylase (OTC) genes by multiplex PCR amplification and sequencing.","date":"2009","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19055470","citation_count":5,"is_preprint":false},{"pmid":"1860901","id":"PMC_1860901","title":"BWTG3 hepatoma cells can acquire phenylalanine hydroxylase, cystathionine synthase and CPS-I without genetic manipulation, but activation of the silent OTC gene requires cell fusion with hepatocytes.","date":"1991","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/1860901","citation_count":5,"is_preprint":false},{"pmid":"35204506","id":"PMC_35204506","title":"Effect of Ornithine Transcarbamylase (OTC) Deficiency on Pregnancy and Puerperium.","date":"2022","source":"Diagnostics (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35204506","citation_count":4,"is_preprint":false},{"pmid":"27083912","id":"PMC_27083912","title":"Toxicity of OTC to Ipomoea aquatica Forsk. and to microorganisms in a long-term sewage-irrigated farmland soil.","date":"2016","source":"Environmental science and pollution research international","url":"https://pubmed.ncbi.nlm.nih.gov/27083912","citation_count":4,"is_preprint":false},{"pmid":"28261508","id":"PMC_28261508","title":"Urea Cycle Defects: Early-Onset Disease Associated with A208T Mutation in OTC Gene-Expanding the Clinical Phenotype.","date":"2017","source":"Case reports in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28261508","citation_count":4,"is_preprint":false},{"pmid":"25573644","id":"PMC_25573644","title":"Hyperammonemic coma in a patient with late-onset OTC deficiency.","date":"2014","source":"La Pediatria medica e chirurgica : Medical and surgical pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/25573644","citation_count":4,"is_preprint":false},{"pmid":"30333473","id":"PMC_30333473","title":"Gene Mutation Analysis and Prenatal Diagnosis of the Ornithine Transcarbamylase (OTC) Gene in Two Families with Ornithine Transcarbamylase Deficiency.","date":"2018","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/30333473","citation_count":4,"is_preprint":false},{"pmid":"22727265","id":"PMC_22727265","title":"Recurrent somnolence in a 17-month-old infant: late-onset ornithine transcarbamylase (OTC) deficiency due to the novel hemizygous mutation c.535C > T (p.Leu179Phe).","date":"2012","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/22727265","citation_count":4,"is_preprint":false},{"pmid":"7786168","id":"PMC_7786168","title":"OTC pharmaceuticals and genotoxicity testing: the paracetamol, anthraquinone, and griseofulvin cases.","date":"1995","source":"Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/7786168","citation_count":3,"is_preprint":false},{"pmid":"23568734","id":"PMC_23568734","title":"[Molecular diagnosis of OTC gene mutation in a Chinese family with ornithine transcarbamylase deficiency].","date":"2013","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23568734","citation_count":3,"is_preprint":false},{"pmid":"30541480","id":"PMC_30541480","title":"Exonic duplication of the OTC gene by a complex rearrangement that likely occurred via a replication-based mechanism: a case report.","date":"2018","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30541480","citation_count":3,"is_preprint":false},{"pmid":"15578616","id":"PMC_15578616","title":"Severe, neonatal-onset OTC deficiency in twin sisters with a de novo balanced reciprocal translocation t(X;5)(p21.1;q11).","date":"2005","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/15578616","citation_count":3,"is_preprint":false},{"pmid":"30175132","id":"PMC_30175132","title":"Mutation Study of Malaysian Patients with Ornithine Transcarbamylase Deficiency: Clinical, Molecular, and Bioinformatics Analyses of Two Novel Missense Mutations of the OTC Gene.","date":"2018","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/30175132","citation_count":3,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46991,"output_tokens":3522,"usd":0.096902},"stage2":{"model":"claude-opus-4-6","input_tokens":6955,"output_tokens":2446,"usd":0.143888},"total_usd":0.24079,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1985,\n      \"finding\": \"The human OTC gene was localized to chromosomal region Xp11.4-Xp21 using somatic cell hybrids, and a frequent RFLP (MspI) was identified; the gene encodes ornithine transcarbamylase, a mitochondrial enzyme of the urea cycle.\",\n      \"method\": \"Somatic cell hybrid mapping, Northern blot, cDNA cloning\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal mapping with somatic cell hybrids, corroborated by Northern blot and cDNA isolation\",\n      \"pmids\": [\"3839070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Newly synthesized mouse OTC precursor (pOTC) is efficiently imported into mitochondria following adenovirus-mediated gene delivery in spf(ash) hepatocytes, with mitochondrial localization confirmed by electron microscope immunolocalization; human OTC precursor showed a block in mitochondrial translocation in the same system.\",\n      \"method\": \"Electron microscope immunolocalization, quantitative morphometry, subcellular fractionation after adenoviral OTC gene delivery\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ultrastructural immunolocalization with functional comparison of mouse vs. human OTC precursor mitochondrial import\",\n      \"pmids\": [\"10448647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Rescue of OTC activity in BWTG3 hepatoma cells (which lack OTC) requires fusion with OTC-positive hepatocytes; the silent OTC gene in hepatoma cells cannot be reactivated by hormones or azacytidine alone, indicating cell-context-dependent transcriptional regulation requiring a liver-specific trans-acting factor.\",\n      \"method\": \"Cell fusion, enzyme activity assay, azacytidine treatment, hormone induction\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic complementation via cell fusion with functional readout, single lab\",\n      \"pmids\": [\"1860901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Zinc supplementation increases hepatic OTC enzymatic activity in cirrhotic rats, with OTC activity positively correlated with serum and hepatic zinc content, suggesting zinc as a modulator of OTC catalytic function.\",\n      \"method\": \"In vivo zinc supplementation, radiochemical OTC enzyme activity assay in cirrhotic rat liver\",\n      \"journal\": \"Journal of trace elements and electrolytes in health and disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single in vivo supplementation study, correlational, no direct mechanistic dissection\",\n      \"pmids\": [\"8019156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Small intestinal OTC activity is more important than hepatic OTC activity for preventing urinary orotic acid excretion; in spf-ash mice carrying an OTC transgene, elevated intestinal OTC activity (30% of control) prevents excess orotic aciduria, whereas hepatic activity alone at ~10% is insufficient.\",\n      \"method\": \"OTC transgenic rescue in spf-ash mice, measurement of urinary orotic acid vs. tissue OTC activity\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic complementation with quantitative tissue-specific activity measurements\",\n      \"pmids\": [\"7827141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Mutations P225L and P225R in OTC codon 225 result in undetectable OTC protein antigen in liver despite near-normal residual enzyme properties (normal pH dependence, Km, stability), suggesting the mutations impair efficient import/folding of the precursor into mitochondria rather than catalytic function per se.\",\n      \"method\": \"Immunoblot for OTC antigen, enzyme kinetic assays (Km for ornithine and carbamoyl phosphate, thermal stability, urea stability), sequencing\",\n      \"journal\": \"Journal of inherited metabolic disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical methods (enzyme kinetics, stability, antigen quantification) in a single study\",\n      \"pmids\": [\"9427144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Transfection of COS1 cells with the Leu148Phe mutant OTC cDNA yielded undetectable OTC enzyme activity, confirming this missense mutation abolishes OTC catalytic function.\",\n      \"method\": \"Transient transfection (COS1 cells), enzyme activity assay\",\n      \"journal\": \"American journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro expression assay with direct functional readout; single study\",\n      \"pmids\": [\"9056557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In OTC-deficient spf(ash) mice, reduced citrulline availability (30–50% of wild-type) leads to reduced de novo arginine production and a 50% reduction in whole-body nitric oxide production under basal conditions, demonstrating that OTC-derived citrulline is required to sustain NO synthesis via the citrulline-arginine-NO pathway.\",\n      \"method\": \"Stable isotope tracer infusion (LC-MS measurement of [15N]citrulline→[15N]arginine→NO flux) in vivo in spf(ash) mice\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vivo isotopic flux analysis with multiple tracers measuring citrulline production, de novo arginine synthesis, and NO production simultaneously\",\n      \"pmids\": [\"18697914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Ornithine supplementation in spf(ash) mice restores ureagenesis, reduces plasma ammonia, and normalizes 15N transfer from glutamine to urea, demonstrating that ornithine availability is rate-limiting for OTC-dependent urea cycle flux under conditions of unbalanced amino acid loads.\",\n      \"method\": \"Multiple stable isotope tracer infusion in vivo ([13C18O]urea, [15N]glutamine tracers) in conscious spf(ash) mice\",\n      \"journal\": \"The Journal of nutrition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vivo multi-tracer kinetic analysis with rigorous controls; directly demonstrates ornithine as rate-limiting substrate for OTC\",\n      \"pmids\": [\"16772445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A heterozygous single nucleotide substitution (c.-366A>G) in the OTC promoter disrupts the interaction of the promoter with an upstream enhancer, reducing transcriptional activity; the OTC promoter requires this upstream enhancer for full activity, and the interaction is necessary for liver-specific OTC expression.\",\n      \"method\": \"Dual luciferase reporter assay, transcription start site mapping, promoter-enhancer interaction functional studies\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional reporter assay with mutagenesis and promoter-enhancer dissection; single lab\",\n      \"pmids\": [\"20127982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The spf/ash mutation (c.386G>A; p.R129H) causes aberrant splicing via partial use of a cryptic 5' splice site 48 bp into intron 4 of the mouse Otc gene, resulting in partial intron 4 retention. In the equivalent human OTC patient, the same nucleotide change instead causes exon 4 skipping or use of a cryptic splice site at c.386+4. Both result in ~3–6% residual OTC enzyme activity. The divergent splicing outcomes are reproduced in minigene assays.\",\n      \"method\": \"RT-PCR of liver tissue, minigene splicing assay, antisense oligonucleotide experiments, enzyme activity assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — splicing mechanism dissected in native tissue and minigene, with species comparison and functional enzyme activity\",\n      \"pmids\": [\"25853564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"OTC protein is expressed in a small subset of nitrergic (nNOS-positive) neurons in the adult human brain, as shown by double immunolabeling for OTC and nNOS, suggesting that OTC-generated citrulline supports NO production in these neurons by enhancing arginine bioavailability.\",\n      \"method\": \"Double immunofluorescence labeling (OTC + nNOS) in human brain sections\",\n      \"journal\": \"Metabolic brain disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single immunohistochemical study, functional implication inferred, not directly tested\",\n      \"pmids\": [\"28868581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Subtle intronic sequence differences at positions +10-11 downstream of the OTC exon 4 cryptic 5'ss confer preferential binding to the TIA1 splicing factor in the mouse but not human genomic context, explaining species-specific splicing outcomes from the c.386G>A mutation and differential responsiveness to engineered U1snRNA therapeutics.\",\n      \"method\": \"RNA pulldown assay (TIA1 binding), minigene splicing assay with nucleotide swap mutants, U1snRNA co-expression in hepatoma cells\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic dissection with RNA pulldown, mutagenesis, and functional splicing readout; multiple orthogonal methods\",\n      \"pmids\": [\"34906067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Common polymorphic OTC variants (p.Lys46Arg and p.Gln270Arg) modulate OTC enzymatic activity in cis: the minor allele of p.Gln270Arg significantly enhanced wild-type OTC activity and partially rescued activity of the pathogenic p.Arg40His allele in vitro.\",\n      \"method\": \"In vitro enzymatic activity assay of recombinant OTC variants, structural analysis\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzymatic assay with multiple allelic combinations; single lab\",\n      \"pmids\": [\"34015158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"An OTC promoter variant (c.-106C>A) in a conserved HNF4α binding site reduces OTC promoter-driven expression >5-fold in a dual-luciferase assay, and this reduction is maintained in the presence of the upstream OTC enhancer, mechanistically explaining late-onset, stress-triggered hyperammonemia in hemizygous males.\",\n      \"method\": \"Dual-luciferase reporter assay with wild-type and mutant OTC promoter constructs, with and without upstream enhancer\",\n      \"journal\": \"Journal of inherited metabolic disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter assay with enhancer dissection; single lab but clear quantitative result\",\n      \"pmids\": [\"35605046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A high-throughput functional assay measuring OTC activity in yeast for 1,570 individual amino acid substitutions (84% of all SNV-accessible missense mutations) identified a 13 amino acid domain (the SMG loop) whose function is required in human cells but not in yeast, and demonstrated score ranges corresponding to clinically relevant levels of OTC activity impairment.\",\n      \"method\": \"High-throughput yeast-based functional assay for OTC activity, clinical variant benchmarking, protein structure analysis\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — large-scale functional assay covering most missense variants, validated against known clinical classifications, with structural interpretation\",\n      \"pmids\": [\"37146589\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"OTC (ornithine transcarbamylase) is a mitochondrial enzyme that catalyzes the conversion of ornithine and carbamoyl phosphate to citrulline as the second step of the urea cycle; its precursor is synthesized in the cytoplasm and imported into mitochondria, where it functions as a trimer, and OTC-derived citrulline is required for de novo arginine synthesis and basal nitric oxide production, while its transcription is controlled by a liver-specific promoter-enhancer interaction dependent on HNF4α binding, and its pre-mRNA splicing is regulated by context-specific splice-site recognition factors including TIA1.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"OTC (ornithine transcarbamylase) is a mitochondrial matrix enzyme that catalyzes the condensation of ornithine and carbamoyl phosphate to form citrulline, constituting the second committed step of the urea cycle. OTC-derived citrulline is essential not only for ureagenesis—where ornithine availability is rate-limiting for cycle flux—but also for de novo arginine synthesis and basal nitric oxide production via the citrulline–arginine–NO pathway [PMID:18697914, PMID:16772445]. The OTC precursor is synthesized in the cytoplasm and imported into the mitochondrial matrix, where disease-causing mutations such as P225L/R can impair translocation or folding rather than catalysis per se [PMID:9427144, PMID:10448647]. Liver-specific OTC transcription depends on a promoter–enhancer interaction requiring an HNF4α binding site, and the pre-mRNA is subject to species-specific alternative splicing controlled by differential TIA1 recognition of intronic sequences flanking the spf/ash mutation site [PMID:20127982, PMID:35605046, PMID:34906067].\",\n  \"teleology\": [\n    {\n      \"year\": 1985,\n      \"claim\": \"Mapping OTC to Xp11.4–Xp21 and cloning its cDNA established the gene's chromosomal identity and linked it to X-linked ornithine transcarbamylase deficiency.\",\n      \"evidence\": \"Somatic cell hybrid mapping, Northern blot, and cDNA cloning in human cells\",\n      \"pmids\": [\"3839070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Gene structure (intron–exon organization) not yet defined\", \"No functional reconstitution of enzyme activity from cloned cDNA\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Demonstration that the OTC precursor must be imported into mitochondria for function—and that liver-specific trans-acting factors are required for OTC transcription—established two distinct regulatory layers: post-translational targeting and tissue-restricted gene expression.\",\n      \"evidence\": \"Electron microscope immunolocalization after adenoviral gene delivery (mitochondrial import); cell fusion experiments showing OTC reactivation only upon complementation with OTC-positive hepatocytes\",\n      \"pmids\": [\"10448647\", \"1860901\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the liver-specific trans-acting factor(s) not determined\", \"Species-specific differences in precursor import (mouse vs. human) unexplained\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Transgenic rescue in spf-ash mice revealed that intestinal OTC activity contributes more than hepatic activity to preventing orotic aciduria, establishing tissue-specific functional contributions of OTC beyond the liver.\",\n      \"evidence\": \"OTC transgene expression in spf-ash mice with quantitation of urinary orotic acid and tissue OTC activity\",\n      \"pmids\": [\"7827141\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of intestinal vs. hepatic OTC contribution to whole-body nitrogen balance not fully dissected\", \"Single transgenic line studied\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Characterization of disease-causing missense mutations (P225L/R, L148F) separated catalytic defects from import/folding defects, revealing that many pathogenic OTC mutations act by destabilizing the precursor rather than abolishing enzymatic activity.\",\n      \"evidence\": \"Enzyme kinetics (Km, thermal stability) and immunoblot of mutant OTC in patient liver and COS1 transfection\",\n      \"pmids\": [\"9427144\", \"9056557\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vitro import assay to directly measure translocation efficiency of mutant precursors\", \"Structural basis of folding defects unknown at atomic resolution\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Isotopic flux analyses in spf-ash mice demonstrated that OTC-derived citrulline is rate-limiting for de novo arginine synthesis and whole-body NO production, and that ornithine supply is rate-limiting for OTC-dependent ureagenesis, connecting OTC to systemic nitrogen and NO metabolism.\",\n      \"evidence\": \"In vivo stable isotope tracer infusion (15N-citrulline→arginine→NO; 13C-urea) in conscious spf-ash mice\",\n      \"pmids\": [\"18697914\", \"16772445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether citrulline supplementation can fully restore NO production independent of OTC not tested\", \"Contribution of extrahepatic OTC to citrulline-arginine-NO pathway not quantified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of a promoter–enhancer interaction required for full OTC transcription, disrupted by the c.−366A>G variant, defined the cis-regulatory architecture governing liver-specific OTC expression.\",\n      \"evidence\": \"Dual-luciferase reporter assay with promoter-enhancer constructs and mutagenesis\",\n      \"pmids\": [\"20127982\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Chromatin-level interaction (e.g. 3C/Hi-C) not confirmed\", \"Trans-acting factors mediating the enhancer–promoter loop not identified at this stage\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Dissection of the spf-ash mutation (c.386G>A) revealed that the same nucleotide change causes distinct aberrant splicing events in mouse (partial intron retention) vs. human (exon skipping), explaining species-specific residual OTC activity and complicating preclinical modeling.\",\n      \"evidence\": \"RT-PCR of liver RNA, minigene splicing assays, and enzyme activity measurement across species\",\n      \"pmids\": [\"25853564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-acting factor(s) responsible for species-specific splice-site selection not yet identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The species-specific splicing of the spf-ash allele was traced to differential TIA1 binding at intronic positions +10–11 downstream of the cryptic 5′ splice site, and common polymorphic variants (p.Lys46Arg, p.Gln270Arg) were shown to modulate OTC enzymatic activity in cis, refining the genotype–phenotype landscape.\",\n      \"evidence\": \"RNA pulldown for TIA1, minigene nucleotide-swap mutagenesis, recombinant OTC enzyme activity assays\",\n      \"pmids\": [\"34906067\", \"34015158\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TIA1 modulation is therapeutically targetable in patients not established\", \"Structural basis for polymorphic modulation of activity not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A promoter variant (c.−106C>A) in a conserved HNF4α binding site was shown to reduce OTC expression >5-fold, mechanistically explaining late-onset hyperammonemia and confirming HNF4α as a key transcriptional regulator of OTC.\",\n      \"evidence\": \"Dual-luciferase reporter assay with wild-type and mutant promoter ± upstream enhancer\",\n      \"pmids\": [\"35605046\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct HNF4α ChIP at the OTC promoter not shown\", \"In vivo validation of this promoter variant's effect on OTC mRNA levels not performed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A high-throughput functional assay covering 84% of SNV-accessible missense substitutions created a near-complete variant effect map, identifying a 13-amino-acid SMG loop required in human but not yeast cells and enabling clinical variant classification at scale.\",\n      \"evidence\": \"Yeast-based OTC activity assay for 1,570 individual substitutions, benchmarked against clinical data and protein structure\",\n      \"pmids\": [\"37146589\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SMG loop function in human cells not mechanistically dissected\", \"Yeast assay may not capture all mammalian-specific folding/import defects\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for how disease mutations differentially affect mitochondrial import versus catalytic function, the full complement of trans-acting factors controlling OTC promoter–enhancer looping in vivo, and whether extrahepatic OTC (intestinal, neuronal) can be therapeutically augmented to compensate for hepatic deficiency.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No atomic-resolution structure of human OTC with bound precursor signal peptide\", \"In vivo chromatin conformation at the OTC locus not mapped\", \"Functional significance of neuronal OTC expression not experimentally validated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 7, 8, 13, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 1, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [7, 8, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TIA1\",\n      \"HNF4A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}